Hormonal
Unimolecular GLP-1/GIP co-agonists (e.g., tirzepatide) produce superior weight loss and glycemic control compared to GLP-1 receptor agonists alone in patients with type 2 diabetes and obesity.
If you have type 2 diabetes or obesity, current GLP-1 medications (like semaglutide) are effective but not the most powerful option available. Newer 'co-agonist' drugs (like tirzepatide) that target both GLP-1 and GIP receptors have shown greater weight loss and better blood sugar control in clinical trials. While these are injections, they are given once a week. The main trade-off is potential gastrointestinal side effects like nausea, though these may be less severe than with some GLP-1-only drugs. Consult your doctor to see if this advanced therapy is appropriate for your specific health profile.
Multiple co-agonist combinations exhibit promising clinical efficacy, notably tirzepatide and investigational amylin combinations. Simultaneously, increasing doses of GLP-1R agonists such as semaglutide produces substantial weight loss, raising the bar for the development of new unimolecular co-agonists. Collectively, the available data suggest that new co-agonists with robust efficacy should prove superior to GLP-1R agonists alone to treat metabolic disorders.
Why this rating
The paper reviews robust preclinical data and early-phase human trials (Phase 1/2) showing superiority, but notes that long-term efficacy and comparison to bariatric surgery remain areas for further study.
Source
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio et al. · Molecular Metabolism · 2020
DOI 10.1016/j.molmet.2020.101090
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →